Market capitalization | $3.88b |
Enterprise Value | $3.78b |
P/E (TTM) P/E ratio | 42.08 |
EV/FCF (TTM) EV/FCF | 55.71 |
EV/Sales (TTM) EV/Sales | 10.90 |
P/S ratio (TTM) P/S ratio | 11.20 |
P/B ratio (TTM) P/B ratio | 22.02 |
Revenue growth (TTM) Revenue growth | 1,341.63% |
Revenue (TTM) Revenue | $346.73m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
9 Analysts have issued a TG Therapeutics, Inc. forecast:
9 Analysts have issued a TG Therapeutics, Inc. forecast:
Dec '23 |
+/-
%
|
||
Net Profit | 13 13 |
106%
106%
|
|
Depreciation and Amortization | 0.42 0.42 |
19%
19%
|
|
Stock Compensation | 38 38 |
98%
98%
|
|
Operating Cash Flow | -31 -31 |
82%
82%
|
|
Investments | - - |
-
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -31 -31 |
82%
82%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.
Head office | United States |
CEO | Michael Weiss |
Employees | 264 |
Founded | 1993 |
Website | www.tgtherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.